Találati lista | Tudóstér

001-es BibID:	BIBFORM121591
035-os BibID:	(scopus)85191105736 (wos)001103520000001
Első szerző:	Vermeire, Séverine
Cím:	Early Versus Late Use of Vedolizumab in Ulcerative Colitis : Clinical, Endoscopic, and Histological Outcomes / Vermeire Séverine, Hanzel Jurij, Löwenberg Mark, Ferrante Marc, Bossuyt Peter, Hoentjen Frank, Franchimont Denis, Palatka Károly, Peeters Harald, Mookhoek Aart, de Hertogh Gert, Molnár Tamás, van Moerkercke Wouter, Lobatón Triana, Clasquin Esmé, Hulshoff Melanie S., Baert Filip, D'Haens Geert, LOVE-UC study group
Dátum:	2024
ISSN:	1873-9946
Megjegyzések:	Background and Aims: We explored the potential for differential efficacy of vedolizumab between early and late ulcerative colitis [UC] with evaluation of clinical, endoscopic, and histological endpoints. Methods: This was a multicentre, multinational, open-label study in patients with moderately-to-severely active UC, defining early UC by a disease duration <4 years and bio-naïve and late UC by a disease duration > 4 years and additional exposure to tumour necrosis factor antagonists. Patients received standard treatment with intravenous vedolizumab for 52 weeks [300 mg Weeks 0, 2, 6, every 8 weeks thereafter without escalation]. The primary endpoint was corticosteroid-free clinical remission with endoscopic improvement [total Mayo score ?2 with no subscore >1] at both Weeks 26 and 52. Results: A total of 121 patients were included: in the "early" group, 25/59 [42.4%] achieved the primary endpoint versus 19/62 [30.6%] in the "late" group [p = 0.18]. There were no significant differences between the two groups in endoscopic improvement [Week 26: "early" 32/59 [54.2%] versus "late" 29/62 [46.8%]; p = 0.412; Week 52: 27/59 [45.8%] versus 25/62 [40.3%]; p = 0.546] or in histological remission [Robarts Histopathology Index <3 without neutrophils in the epithelium and lamina propria] [Week 26: 24/59 [40.7%] versus 21/62 [33.9%]; p = 0.439; Week 52: 22/59 [37.3%] versus 22/62 [35.5%]; p = 0.837]. Conclusions: No significant differences in clinical, endoscopic, and histological outcomes were observed between "early" and "late" disease.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk anti-integrin biologic inflammatory bowel disease LOVE-UC Trial
Megjelenés:	Journal of Crohns & Colitis. - 18 : 4 (2024), p. 540-547. -
További szerzők:	Hanzel, Jurij Löwenberg, Mark Ferrante, Marco Bossuyt, Peter Hoentjen, Frank Franchimont, Denis Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Peeters, Harald Mookhoek, Aart de Hertogh, Gert Molnár Tamás (orvos Szeged) van Moerkercke, Wouter Lobatón, Triana Clasquin, Esmé Hulshoff, Melanie S. Baert, Filip D'Haens, Geert LOVE-UC study group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: